Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VIVK
to da moon Alice! lol
http://finance.yahoo.com/news/Vivakor-Announces-Receipt-of-pz-994033674.html?x=0&.v=1
OPTZ
looks like signal failed to break thru adx so this will need more time imo But MMTC lookin good :) :
http://stockcharts.com/h-sc/ui?s=OPTZ
OPTZ
another adx pinch Should ripen soon imo!
MMTC
looks like adx pinch coming up. Also PCFG some low hanging fruit right now.
http://stockcharts.com/h-sc/ui?s=MMTC
ANX
ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study
UP PM already at 2.92
ANX 2.83 0.00
On Wednesday December 15, 2010, 8:00 am EST
SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) to schedule a meeting for the purpose of discussing its product candidate ANX-514 (docetaxel emulsion for injection). The FDA is expected to set the meeting date within 60 days of receiving the request from ADVENTRX.
"We have performed an extensive analysis of the data from our bioequivalence study of ANX-514, as well as on results from other trials using Taxotere®, and plan to discuss our findings at the meeting," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
"Based in part on the substantial variability observed with Taxotere as reported in the literature, we believe the transitory elevations in total docetaxel concentrations for ANX-514 do not affect adversely its safety or efficacy relative to Taxotere. However, the FDA is the final arbiter of safety and efficacy and, following our meeting, we will provide an update on the next steps and requirements for advancing ANX514 toward an NDA submission," Mr. Culley continued.
About ANX-514
ANX-514 is a novel emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is being developed to reduce the incidence and severity of side effects associated with detergents, such as hypersensitivity reactions.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the timing of a meeting with the FDA to discuss ANX-514 and ADVENTRX's ability to determine next steps and requirements for advancing ANX-514 toward an NDA submission based on the meeting and the safety and efficacy of ANX-514 relative to Taxotere. Actual events or results may differ materially from those expressed or implied by the forward-looking statements in this press release due to a number of risks and uncertainties, including, without limitation: the potential for the FDA to delay meeting with ADVENTRX regarding ANX-514; the potential for the FDA to disagree with ADVENTRX's conclusions regarding the safety and efficacy of ANX-514 relative to Taxotere based on the data from its bioequivalence study or to determine that ANX-514 and Taxotere are not bioequivalent, including as a result of determining that increased total docetaxel concentrations during and shortly following the end of the infusion are clinically significant; the risk that the FDA and other regulatory authorities will require additional nonclinical and/or clinical activities to support regulatory filings, including prior to the filing or the approval of a New Drug Application (NDA) for ANX-514, which activities may increase the cost and timeline to NDA filing or approval and may negatively impact ADVENTRX's ability to raise additional capital for development of and/or partner ANX-514; ADVENTRX's dependence on the success of ANX514 and the possibility that ADVENTRX does not receive regulatory approval of ANX-514 on a timely basis, or at all; the potential that changes made in transferring the manufacturing process for ANX-514 may result in a lack of comparability between the commercial product and the material used in the bioequivalence study and cause the FDA to require ADVENTRX to perform additional nonclinical or clinical studies; difficulties or delays in obtaining regulatory approval for ANX-514, even if regulatory authorities determine ANX-514 and Taxotere are bioequivalent, including the potential for automatic injunctions regarding FDA approval of ANX-514 and other challenges by patent holders during the Section 505(b)(2) process; difficulties or delays in manufacturing and marketing ANX-514, including validating commercial manufacturing processes and manufacturers, as well as suppliers; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence studies, regulatory submissions, CMC activities and other important aspects of the ANX-514 development program, including analysis of the bioequivalence study data, and that such third parties may fail to perform as expected; the risk that ADVENTRX may not be able to successfully commercialize ANX-514 if it receives regulatory approval; the risk that ADVENTRX will pursue development activities at levels on timelines, or will incur unexpected expenses, that shorten the period through which its operating funds will sustain it; the potential for ADVENTRX to enter into a merger or other business combination in connection with a new product candidate acquisition resulting in a successor entity that focuses its resources on developing products and product candidates other than ADVENTRX's existing product candidates, including ANX-514; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Follow Yahoo! Finance on Twitter; become a fan on Facebook.
Related Headlines
ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study - PR Newswire
Small-cap Biotech Executives Reveal Innovative Technologies at NYSSA Conference - Business Wire
ADVENTRX PHARMACEUTICALS INC Financials - EDGAR Online Financials
ADVENTRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - EDGAR Online
ADVENTRX Reports Third Quarter Financial Results - PR Newswire
Related Blog Headlines
ADVENTRX: Improving Performance, Safety - Zacks
Related Message Boards
ADVENTRX Pharmaceuticals, Inc.
1 commentShow: Newest FirstOldest FirstHighest RatedMost Replied Post a comment 0 users liked this comment Please sign in to rate this comment up. Please sign in to rate this comment down. 0 users disliked this commentRYAN Wed Dec 15, 2010 11:40 am EST Report Abuse ANX should go up to about $5-6/share the day this gets approved!Reply
Post a comment
Sign in to post a comment, or Sign up for a free account. Top Stories
TD Bank to buy Chrysler Financial for $6.3B - AP
Soon the government check won't be in the mail - AP
Toyota to pay $32.4 million in extra fines - AP
ConAgra Foods 2Q earnings fall, meet Street view - AP
AdChoices
Tech Ticker Recent Posts
10 Things You Need To Know Before The Opening Bell - Gregory White
More Than Two Years After Lehman’s Crash, NY's Cuomo Targets Auditor Ernst & Young - Peter Gorenstein
Muni Bonds: The Next New Crisis? - Aaron Task
View More
Subscribe to Topics
Top Stories
Add Alert
anx Headlines
Add Alert
See all RSS links
OTGI
some nice buying pressure
ANX
choo choo! lol The NDA has been filed:
http://finance.yahoo.com/news/ADVENTRX-Submits-Exelbine-New-prnews-1520695492.html?x=0&.v=1
IDOI
MMs dropping off only 3 left now!
EMLL smokin!
This dog just took a flea bath.
EMLL nice chart
Nice MFI and RSI has lots of upside imo.
morning all!
got my sights set on ISIM and GCMN today. Price of gold keeps moving up and GCMN has been attracting some buyers lately. ISIM has been acting feisty last few days. Hit 24 yesterday! glta
MFLU has a new buy recommendation
http://www.dawsonjames.com/portal/MFLU_Initiation_10_18_2010.pdf
ICOA
huge volume today. Maybe news coming on monday about share reduction.
ICOA
technicals are screaming breakout near imo. I grabbed a few yesterday.
GGII could go
some nice news with 250m float. 4 X 1 now. :)
JOEZ
p/u a few on the dip today. Earnings are due out today. Could be just shorts here but their sales been growing at a 50% clip.
it's around 2 bucks
did a 1/25 r/s back a few months ago. The presplit price is about 8c so it's pretty cheap here imo.
hello mick
it may be done for now until they have some good news imo. Anx may be set to move this month if they file their new nda with the fda. It should be approved this time imo.
IKAN
making a move here! up 8c
MMUH
lot of bids on this one. Grabbed some 4s.
ICTY
nice and green today! :)
ICTY
broke into double zeros yesterday. Am expecting more today. glta
morning everyone!
ANX
some good news from yesterday:
ADVENTRX Announces 12-Month Stability Data Results for ANX-530
SAN DIEGO, Sept 14, 2010 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals,
Inc. (ANX) today announced the results of stability tests performed on samples of
ANX-530 (vinorelbine injectable emulsion), or Exelbine(TM), manufactured at the
Company's intended commercial manufacturing site. The 12-month stability data are
consistent with the stability data collected at 6 and 9 months and will support
the Company's submission of a New Drug Application (NDA) for Exelbine, which the
Company expects to take place in the fourth quarter of this year.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product
candidates are being developed to improve the performance of existing anti-cancer
drugs by addressing limitations associated principally with their safety and use.
More information can be found on the Company's web site at
http://www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not
a description of historical facts are forward-looking statements that are based
on ADVENTRX's current expectations and assumptions. Examples of forward-looking
statements include, but are not limited to, statements regarding ADVENTRX's
submission of an Exelbine NDA. Actual events or results may differ materially
from those expressed or implied by the forward-looking statements in this press
release due to a number of risks and uncertainties, including, without
limitation: the risk that future stability testing results do not support
comparability between ADVENTRX's prior and intended commercial manufacturing
sites or a commercially-viable expiration dating period; the risk that the FDA
does not accept a submitted Exelbine NDA for review, including as a result of
identifying clinical or nonclinical reasons for a refusal-to-file or identifying
CMC reasons that were not identified in the refusal-to-file of the previously
submitted Exelbine NDA; the potential that changes made in transferring the
manufacturing process for Exelbine may result in a lack of comparability between
the commercial product and the material used in the bioequivalence trial, and
that the FDA may require ADVENTRX to perform additional nonclinical,
bioequivalence or clinical studies; the potential for the FDA to impose other
requirements to be completed before or after approval of an Exelbine NDA; and
other risks and uncertainties more fully described in ADVENTRX's press releases
and periodic filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are available at
http://www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the date when made. ADVENTRX does not intend to revise or
update any forward-looking statement set forth in this press release to reflect
events or circumstances arising after the date hereof, except as may be required
by law.
NDA submission now coming soon and they should get approved which will send this puppy flying imo.
USAE up on some nice news!
grabbed some .12s
Abix looks good
Nsmg may be oversold. More bang for your buck imo but it all depends on one's flavor I guess. gl
EARL is coming
got Nsmg?
NSMG playing catchup
Wow! they have 6 filings on the same day. Now if they get the pr campaign going you could have a real zesty pop in sp short term imo.
SMPP
could go I like the macd on this one from the chart:
http://stockcharts.com/h-sc/ui?s=SMPP
morning Dave and everyone!
EMLL
only this from yesterday but I think more people are buying today cause Vert has backed off imo (he is the axe here):
El Maniel International, Inc. Adjusts Share Structure Toward Flexibility; Market Appeal
Date : 08/12/2010 @ 9:35AM
Source : GlobeNewswire Inc.
Stock : El Maniel International, Inc. (EMLL)
Quote : 0.0014 0.0005 (55.56%) @ 1:22PM
El Maniel International, Inc. Adjusts Share Structure Toward Flexibility; Market Appeal
EL Maniel Intl (BB) (OTCBB:EMLL)
Intraday Stock Chart
Today : Friday 13 August 2010
El Maniel International, Inc. (OTCBB:EMLL) Director and CEO Jamie Khoo announces today that the company has adjusted its share structure as part of an initiative to attract market support in line with its recent successes as a company.
The company's restructuring includes an authorized share count of 5,000,000,000 with a 2,292,110,000 outstanding. "It's important to note that 2,000,000,000 of these outstanding shares are held by company Directors and are restricted for a period of 1 year. We believe, again, this new structure will allow for flexibility in regards to our opportunities which should lend itself to overall market appeal for prospective partners and shareholders," states Jamie Khoo.
The company's Directors have elected to increase the authorized share count which will allow the company to fully realize its goals with these ventures toward overall growth including stated interest involving international mergers and acquisition. "We are confident that the expansion will result in a collective win for EMLL as we expedite these exciting, viable projects with frequent updates hereon," states Jamie Khoo. "The company has experienced tremendous growth in Q2 with the company's recent successes, which include its 70% stamp and collectibles company acquisition with assets currently valued at $4.5 million; as well as the acquisition of an oil terminal on a 5 acres of land surrounding, with a potential 24 million gallons of petroleum products per year."
EMLL will continue to advance the infrastructure project of its oil terminal located in Eastern Pennsylvania where several wholesalers have been interviewed and EMLL has received a better than expected response to their future products to be sold at the terminal site. In an effort to benefit from Pennsylvania as one of the foremost states in the USA that promotes alternative energy, EMLL has introduced its concepts and future project of biodiesel to various local organizations both on a County and State level to much interest. The current potential changes at the site include the repainting of the tanks with the EMLL logo. Jamie Khoo expects that the initial stages of the refurbishing of the site will be completed by this Fall and full operations in effect shortly thereafter.
"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. These risks and uncertainties include the Company's entry into new commercial businesses, the risk of obtaining financing, recruiting and retaining qualified personnel, and other risks described in the Company's Securities and Exchange Commission filings. The forward-looking statements in this press release speak only as of the date hereof, and the Company disclaims any obligation to provide updates, revisions or amendments to any forward-looking statement to reflect changes in the Company's expectations or future events.
CONTACT: El Maniel International, Inc.
Media Relations
2125754789
info@elmaniel.com
Suite 618, 580 5th Avenue
New York, New York 10036
EMLL
up 33% and bouncing. Just hope Vert stays out
IKAN
nice post from jeremy richards seeking alpha:
Ikanos Communications Inc. (IKAN), is a bargain-priced broadband semiconductor company. It is trading at just $1.10 a share and I have been accumulating a sizable long position while taking advantage of the current price drop.
TechnicalsMy chart program alerted a new buy trend on Ikanos with money flow moving in. This suggests a future upward move. I expect Ikanos to test the 50 day moving average of $1.62 area over the next 3 months. Ikanos should test the 200 day moving average of $2.29 over the next 6 to 12 months, which represents over 100% upside reward for new investors.
RestructuringIkanos stock has dropped from a $1.80 close on August 4th prior to the quarterly earnings report. I believe this sell-off is extremely over done, given the fact Ikanos missed its revenue estimate by only $400k and the changes that are taking place. The company is set to rebound given the benefits to be realized from last year's merger and increasing focus on high-margin business with fewer future write-downs of de-emphasized product lines.
FundamantalsCFO Dennis Bencala:
Ikanos' revenue for the second quarter of 2010 was just below our guidance. Overall, Ikanos' revenue continued to be well diversified by region. Our core VDSL business also saw double digit sequential revenue growth from first quarter to second quarter 2010....Ikanos is debt free and has a book value of $1.73. Institutions are holding 30% and insiders hold 44.5%, which indicate the company is very closely-held. Ikanos is trading at a price to sales ratio of only 0.3 and trades with a forward P/E ratio of 7. I expect the stock price will rebound to the $1.40 area in the very near term and $1.62 in the next 3 months. Investors buying now have very limited downside risk with decent upside reward.
Disclosure: Long IKAN
MFLU 2nd qtr out
eps +1c vs. -2c from last year. Revs up 30%. Looks like it is turning around imo:
Microfluidics International Corporation Announces Second Quarter 2010 Financial Results
Microfluidics Intl Corp (BB) (OTCBB:MFLU)
Intraday Stock Chart
Today : Wednesday 11 August 2010
Microfluidics International Corporation (OTC Bulletin Board: MFLU), today reported unaudited financial results for the second quarter ended June 30, 2010.
(Logo: http://photos.prnewswire.com/prnh/20090811/NE59652LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO )
Second Quarter and Recent Accomplishments:
Generated $4.5 million in revenue for the second quarter, a 30% increase over the same period in 2009
Generated net income for the second quarter of $143,000 or $0.01 per share, compared to a loss of $177,000, or $0.02 per share, in the second quarter of 2009
Achieved $396,000 in earnings before interest, taxes, depreciation and amortization (EBITDA)
Achieved 64% gross margin
Began to shipped the LV1 low volume Microfluidizer® in the quarter
"The second quarter of 2010 marks the fourth consecutive quarter that Microfluidics has generated net income and consistently achieved our 60% gross margin target," said Michael C. Ferrara, President and Chief Executive Officer of Microfluidics. "In addition, we currently have more new products available than ever before in the history of the Company. I'm pleased with the second quarter and first half of 2010."
"We are extremely pleased to announce another positive quarter leading to an excellent first half of the year," said Peter Byczko, Vice President of Finance and Chief Accounting Officer. "Our financial results reflect demand for our technology which enabled the company to achieve better operating margins. We have improved our working capital efficiency over last year creating positive cash flow and strengthening our balance sheet."
Second Quarter Financial Results:
Revenues for the three months ended June 30, 2010 were $4.5 million, an increase of $1.0 million, or 30%, as compared to revenues of $3.5 million for the three months ended June 30, 2009. North American revenues were $2.4 million, an increase of 58%, as compared to $1.5 million in the second quarter of 2009. Foreign revenues were $2.1 million, an increase of $148,000, or 7.7%, from $1.9 million for the second quarter of 2009. The increase in revenues is principally attributable to an increase in the sale of lab machines and spare parts. Our gross margin increased to 64% in the second quarter of 2010. Net income was $143,000, or $0.01 per diluted share, for the three months ended June 30, 2010 as compared to a net loss of $177,000, or $0.02 per diluted share, for the same period in 2009.
EBITDA was $396,000 for the three months ended June 30, 2010 compared with a $48,000 EBITDA for the same period in 2009. EBITDA is not a financial measure calculated in accordance with generally accepted accounting principles (GAAP). A reconciliation of GAAP net income to Non-GAAP EBITDA is provided in the financial tables that accompany this release and is discussed under the section below titled "Non-GAAP Financial Measures."
Year to Date Financial Results:
Revenues for the six months ended June 30, 2010 were $8.8 million, an increase of $1.8 million, or 26%, as compared to revenues of $7.0 million for the six months ended June 30, 2009. Net income was $249,000, or $0.02 per diluted share, for the six months ended June 30, 2010 as compared to an $867,000 net loss, or $0.08 per diluted share, for the same period in 2009.
EBITDA was $762,000 for the six months ended June 30, 2010 compared with a $420,000 negative EBITDA for the same period in 2009.
Live Webcast:
Microfluidics International Corporation will host a webcast on Tuesday, August 10, 2010 at 8:30 a.m. Eastern Time. Participants are invited to attend the call by visiting www.microfluidicscorp.com or by dialing 866-730-5767 (within the United States) or 857-350-1591 (outside the United States). The pass code for participants is 17982013.
A replay will be available approximately two hours after the live call through August 18, 2010. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The pass code for participants is 45623626. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.
morning everyone!
With the volume here
and the large drop in sp this could jump tomorrow am when this hits more computer scans tonight imo.
EMLL down 99%
trying to bounce here!
I have been trying to buy
but orders won't go thru!
Maybe no one wants to sell? lol
EMLL anyone catch this
down 99% today! lol